Tiziana Life Sciences Ltd TLSA
0.61 USD -0.06 (-8.80%)
At closeNov 10, 2026, 6:31 PM EST
0.62 +0.01 +1.61%
After hours · Nov 10, 6:31 PM ET
0.61 Day range 0.6847
0.57 52-week range 1.90
- YTD
- -59.05%
- 1 year
- -65.13%
News
seekingalpha.com Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript Tiziana Life Sciences Ltd (TLSA) Discusses Positive Phase 2a INFORM-MS Results for Intranasal Foralumab in Nonactive Secondary Progressive Multiple Sclerosis Transcript
benzinga.com Tiziana Life Sciences Highlights Phase 2a INFORM-MS Success For Intranasal Foralumab, Showing Reduced Neuroinflammation And Improved Fatigue In Secondary Progressive MS Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
globenewswire.com Tiziana KOL Call Highlights Consistency Between Positive Phase 2a INFORM-MS Topline Results and Longer-Term Clinical Benefits Observed in Expanded Access Program for Patients with Non-Active Secondary Progressive Multiple Sclerosis Treated with Intranasal Foralumab BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
globenewswire.com Tiziana to Host Investor Call with Key Opinion Leaders to Discuss Positive Phase 2a INFORM-MS Topline Results BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
reuters.com Tiziana's experimental MS treatment meets main goals in mid-stage study Tiziana's experimental MS treatment meets main goals in mid-stage study
benzinga.com Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as…
globenewswire.com Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
proactiveinvestors.com Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient has begun dosing in its Phase 2 trial of intranasal foralumab in early or mild Alzheimer's disease, with topline data expected in the…- benzinga.com Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027 Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
globenewswire.com Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…
proactiveinvestors.com Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug Administration to grant orphan drug designation to its intranasal foralumab for multiple system atrophy (MSA), a rare…
proactiveinvestors.com Tiziana doses first three patients in ALS trial of nasal antibody foralumab Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the first three participants have received their first dose of intranasal foralumab in a Phase 2a trial in people living with amyotrophic lateral…- benzinga.com Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
proactiveinvestors.com Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Monday the last patient has completed their final visit in the company's Phase 2a clinical trial evaluating intranasal foralumab in patients with…
benzinga.com Tiziana Completes Phase 2a MS Trial, Topline Data Due In October Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
benzinga.com Why Is Tiziana Life Sciences Stock Gaining Thursday? Tiziana Life Sciences (TLSA) stock jumps 21% following an MOU to test intranasal foralumab combo therapy for MS.
proactiveinvestors.com Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million. Akanda (NASDAQ:AKAN) stock rose 15.07%…
proactiveinvestors.com Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the biotech's approach to modulating central nervous system inflammation as a…
proactiveinvestors.com Dow climbs as stocks rebound on earnings, falling Treasury yields 3:40pm: Small cap wrap Tiziana Life Sciences Ltd (NASDAQ:TLSA) received a Buy rating and $7 price target from BTIG, which highlighted its nasal anti-CD3...
benzinga.com This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).
benzinga.com BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7 BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.
proactiveinvestors.com Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026 Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of intranasal foralumab at ALS Nexus 2026 in Orlando, Florida, on Monday. The…- benzinga.com Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026 Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
globenewswire.com Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026 BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
proactiveinvestors.com Gemini Pro delay leaves Google with an empty flagship tier Polymarket, the crypto-based prediction platform, puts the probability of no new Gemini Pro release before 30 September at 69%. Every specific launch date...
proactiveinvestors.com Tiziana Life Sciences announces CEO share purchase Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its CEO Ivor Elrifi increased his stake in the company through the purchase of 321,423 common shares on Nasdaq...
globenewswire.com Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its…
benzinga.com Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition Biotechnology firm Tiziana Life Sciences Ltd. (NASDAQ:TLSA) on Friday revealed promising quantitative PET imaging results from the third patient participating in its Phase 2 clinical trial.
benzinga.com Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition Tiziana Life Sciences reports reduced brain inflammation in its third Phase 2 trial patient treated with intranasal foralumab for MSA.
proactiveinvestors.com Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal…
benzinga.com Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory Activity Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative…
benzinga.com Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026 Top line data readout expected in late Q3/early Q4 INFORM-MS trial is a randomized, double-blind, placebo-controlled Phase 2a trial using Intranasal Foralumab in patients with Non-Active Secondary…- benzinga.com Tiziana Life Sciences Says Its Executive Chairman And Founder, Gabriele Cerrone, Increases Holdings With Purchase Of 15,000 Common Shares At $1.11 Per Share Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal…
- benzinga.com Tiziana Life Sciences Completes Enrollment In Phase 2a Trial Of Intranasal Foralumab For Secondary Progressive Multiple Sclerosis, With Topline Data Expected In Q3 2026 Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that…
- benzinga.com Tiziana Life Sciences' Updated Data From Its Ongoing Expanded Access Program Of Intranasal Foralumab For Non-Active Secondary Progressive Multiple Sclerosis Shows Encouraging Trends In Stabilization Of Disability And Meaningful Improvements In Fatigue Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces updated…
benzinga.com Tiziana Life Sciences Announces Initial Quantitative PET Imaging Results From The First Two Patients With Multiple System Atrophy In Its Phase 2 Clinical Trial Of Forlumab Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces initial…- benzinga.com Tiziana Life Sciences Announces Publication Of Preclinical Data Showing Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation And Improves Cognitive Function Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the…
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus U.S. stock futures were higher on Friday, the slipping in first trading session of 2025. All four index futures advanced in premarket trade.